3-(5-氯-2-氟苯甲酰氨基)吡嗪-2-甲酰胺 | 936564-98-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(5-氯-2-氟苯甲酰氨基)吡嗪-2-甲酰胺
• 英文名称: 3-(5-Chloro-2-fluorobenzamido)pyrazine-2-carboxamide
• 英文别名: 3-[(5-chloro-2-fluorobenzoyl)amino]pyrazine-2-carboxamide
• CAS: 936564-98-6
• 化学式: C₁₂H₈ClFN₄O₂
• 分子量: 294.673
• InChiKey: UDBYRWYBFPAGRP-UHFFFAOYSA-N

物化性质

• 沸点：
  430.2±45.0 °C(Predicted)
• 密度：
  1.554±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  98
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(5-氯-2-氟苯甲酰氨基)吡嗪-2-甲酰胺 在 sodium hydroxide 作用下， 生成
  参考文献：
  名称：

  Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

  摘要：

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.046
• 作为产物：
  描述：

  5-氯-2-氟苯甲酰氯 在 吡啶 、 氨 作用下， 以 乙醇 为溶剂， 生成 3-(5-氯-2-氟苯甲酰氨基)吡嗪-2-甲酰胺
  参考文献：
  名称：

  Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

  摘要：

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.046

文献信息

• Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors
  作者：Pierre Raboisson、Oliver Lenz、Tse-I Lin、Dominique Surleraux、Sarvajit Chakravarty、Annick Scholliers、Katrien Vermeiren、Frederic Delouvroy、Thierry Verbinnen、Kenneth Simmen

  DOI：10.1016/j.bmcl.2007.01.046

  日期：2007.4

  Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-2-fluoro-phenyl)pteridin-4-ylamino]-N-[3-(2-oxopyrrolidin-1-yl)propyl]nicotinamide 36 with a replicon EC50 of 64 nM, associated with a selective kinase inhibitory profile for human JNK kinases 2 and 3 as well as VEGFR-1, 2, and 3 kinases. Moreover, 36 showed an advantageous PK profile in mice. Experiments performed using different replicon constructs suggest that this series of kinase inhibitors might mediate their effect through the HCV non-structural protein 5A (NS5A). (c) 2007 Elsevier Ltd. All rights reserved.